<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04280926</url>
  </required_header>
  <id_info>
    <org_study_id>SAFETY</org_study_id>
    <nct_id>NCT04280926</nct_id>
  </id_info>
  <brief_title>Use of High Sensitivity Cardiac Troponin In Ruling Out Emergency Patients With Acute Myocardial Injury and Infarction</brief_title>
  <acronym>SAFETY</acronym>
  <official_title>Use of High Sensitivity Cardiac Troponin In Safely Ruling Out Emergency Patients With Acute Myocardial Injury and Infarction (SAFETY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hennepin Healthcare Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Siemens Healthineers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hennepin Healthcare Research Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Examine the analytical and clinical performance of Atellica IM TnIH assay for the diagnosis
      and rule out of acute myocardial injury and myocardial infarction in patients presenting to
      the emergency department in whom serial cTnI measurements are obtained on clinical
      indication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Studies addressing the clinical performance of the Siemens Healthineers
      High-Sensitivity Troponin I assay (TnIH) on the Atellica IM analyzer for the diagnosis and
      rule out of acute myocardial injury and myocardial infarction in consecutive patients
      presenting to a United States (US) emergency department are lacking.

      Study objective: Examine the analytical and clinical performance of Atellica IM TnIH assay
      for the diagnosis and rule out of acute myocardial injury and myocardial infarction in
      patients presenting to the emergency department in whom serial cTnI measurements are obtained
      on clinical indication.

      Hypothesis: The Atellica IM TnIH assay will offer an excellent diagnostic performance for
      acute myocardial injury and acute myocardial infarction, as well as expedite the risk
      stratification of patients for early discharge from the emergency department.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute myocardial infarction - Abbott hs-cTnI</measure>
    <time_frame>Day 1</time_frame>
    <description>Adjudicated diagnosis of acute myocardial injury using the Abbott hs-cTnI assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of myocardial infarction - Roche Gen 5 cTnT</measure>
    <time_frame>Day 1</time_frame>
    <description>Adjudicated diagnosis of acute myocardial injury using the Roche Gen 5 cTnT assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of myocardial infarction - Abbott contemporary cTnI</measure>
    <time_frame>Day 1</time_frame>
    <description>Adjudicated diagnosis of acute myocardial injury using the Abbott contemporary cTnT assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>up to 180 days</time_frame>
    <description>any death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac mortality</measure>
    <time_frame>up to 180 days</time_frame>
    <description>death due to cardiac reasons</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated index acute myocardial infarction according to 4th UDMI</measure>
    <time_frame>on admission</time_frame>
    <description>acute myocardial infarction, including sub-types following the Fourth Universal Definition of Myocardial Infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that underwent revascularization</measure>
    <time_frame>up to 180 days</time_frame>
    <description>coronary artery bypass graft surgery or percutaneous coronary intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome - MACE</measure>
    <time_frame>30 days</time_frame>
    <description>Major Adverse Cardiovascular Event - cardiac death, myocardial infarction, revascularization, congestive heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome - MACE</measure>
    <time_frame>180 days</time_frame>
    <description>Major Adverse Cardiovascular Event - cardiac death, myocardial infarction, revascularization, congestive heart failure</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
    <description>Study population: Prospective, observational cohort study of consecutives patients (goal, 2000 patients over 4 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac Troponin Testing</intervention_name>
    <description>Fresh serum or lithium heparin plasma samples will be measured with the Atellica IM TnIH assay (Siemens Heatlhineers).</description>
    <arm_group_label>Cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Excess blood is biobanked after clinical testing for cTnI
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutives patients (goal, 2000 patients over 4 months) presenting to the emergency
        department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin
        Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out
        acute myocardial infarction.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Baseline cTn measurement and at least one additional cTn measurement within 6 hours
             after initial measurement.

          2. At least one 12-lead electrocardiogram

        Exclusion Criteria:

          1. Less than 18 years old

          2. Pregnancy

          3. Trauma

          4. Decline to participate

          5. Did not present through the ED

          6. Transferred from an outside hospital or clinic.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred S Apple, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hennepin Healthcare Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen M Schulz, DC</last_name>
    <phone>612-873-6893</phone>
    <email>kschulz@hhrinstitute.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hennepin Healthcare Research Institute / Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Karen M Schulz, DC</last_name>
      <phone>612-873-6893</phone>
      <email>kschulz@hhrinstitute.org</email>
    </contact>
    <investigator>
      <last_name>Fred S Apple, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 23, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Troponin</keyword>
  <keyword>high-sensitivity cardiac troponin</keyword>
  <keyword>acute myocardial infarction</keyword>
  <keyword>Siemens Atellica</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

